Filing Details
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) filed a Form 8-K with the Securities and Exchange Commission on October 06, 2026, disclosing a material event.
8k filedNASDAQ:TELO
Telomir Pharmaceuticals, Inc. (TELO) Reports Material Event to SEC
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) filed a Form 8-K with the Securities and Exchange Commission on October 06, 2026, disclosing a material event.
At publication ·
What changed
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Telomir Pharmaceuticals filed a Form 8-K with the SEC on October 6, 2026, disclosing a material event requiring shareholder attention.
- The company's stock trades at $1.20 per share with a market capitalization of $50.7 million.
- Form 8-K filings report significant events such as leadership changes, material agreements, acquisitions, or asset sales between regular reports.
- The article does not specify the nature of the material event disclosed in the filing.
Market Context
Telomir Pharmaceuticals, Inc.'s stock currently trades at $1.20 with a market capitalization of $50.7M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Telomir Pharmaceuticals, Inc.'s stock.
All SEC filings for Telomir Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TELO Stock Page
Frequently Asked Questions
Where can I read TELO's SEC filings?
Browse all filings on our TELO SEC filings page.
What types of SEC filings does Telomir Pharmaceuticals, Inc. file?
Public companies like Telomir Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.